Safety Measures for Operating Team and Operation Theater During the Current Scenario of COVID-19

The COVID-19 has become a major threat to Pakistan and worldwide, and has become a significant issue for global health, economy and societies. This rapid spread was occurred from Wuhan, China to most of the part of the world. To elaborate the concept and recommendations regarding the safety precautions in operation theater (O.T) and inside associated team during the current scenario of COVID-19. Many research and review articles were studied to collect information about Covid-19 and strategies published in various journals using the search engine, PubMed and Medline. The COVID-19 has significantly changed all aspects of daily life around the world since very start of this year 2020. SARS-CoV-2 (COVID-19), a novel corona virus, has been infected many healthcare workers. In this perspective, hospitals need a strategy to manage their resources, staff and supplies so that patients receive optimal treatment. A decision tree algorithm was developed that defined the recommendations for safety measures in operation theater and operating procedures, these include identifying and developing an isolation room, administrative measures such as transformations in working flow and procedures, introducing personal protective equipment for the employees and formulating anesthetic clinical guidelines. These control actions are essential to enhance the excellence of care provided to COVID-19 patients and to minimize the risk of spread to other patients or staff. The operating room is a dynamic environment with numerous staff like anesthesiologists, physicians, nurses, O.T attendants and technicians; however, we agree that the containment steps are important in order to improve the standard of treatment provided to COVID-19 patients and to minimize the chance of viral spread to patients other than COVID-19 and hospital staff

Mutational analysis of SARS-CoV-2 ORF6-KPNA2 binding interface and identification of potent small molecule inhibitors to recuse the host immune system

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) surfaced on 31 December, 2019, and was identified as the causative agent of the global COVID-19 pandemic, leading to a pneumonia-like disease. One of its accessory proteins, ORF6, has been found to play a critical role in immune evasion by interacting with KPNA2 to antagonize IFN signaling and production pathways, resulting in the inhibition of IRF3 and STAT1 nuclear translocation. Since various mutations have been observed in ORF6, therefore, a comparative binding, biophysical, and structural analysis was used to reveal how these mutations affect the virus's ability to evade the human immune system. Among the identified mutations, the V9F, V24A, W27L, and I33T, were found to have a highly destabilizing effect on the protein structure of ORF6. Additionally, the molecular docking analysis of wildtype and mutant ORF6 and KPNA2 revealed the docking score of - 53.72 kcal/mol for wildtype while, -267.90 kcal/mol, -258.41kcal/mol, -254.51 kcal/mol and -268.79 kcal/mol for V9F, V24A, W27L, and I33T respectively. As compared to the wildtype the V9F showed a stronger binding affinity with KPNA2 which is further verified by the binding free energy (-42.28 kcal/mol) calculation. Furthermore, to halt the binding interface of the ORF6-KPNA2 complex, we used a computational molecular search of potential natural products. A multi-step virtual screening of the African natural database identified the top 5 compounds with best docking scores of -6.40 kcal/mol, -6.10 kcal/mol, -6.09 kcal/mol, -6.06 kcal/mol, and -6.03 kcal/mol for tophit1-5 respectively. Subsequent all-atoms simulations of these top hits revealed consistent dynamics, indicating their stability and their potential to interact effectively with the interface residues. In conclusion, our study represents the first attempt to establish a foundation for understanding the heightened infectivity of new SARS-CoV-2 variants and provides a strong impetus for the development of novel drugs against them.The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by Qatar University grant No. QUPD CAS-23-24-491. Authors are thankful to the Researchers Supporting Project number (RSP2024R491), King Saud University, Riyadh, Saudi Arabia. This work has been also supported by the Qatar University grant n. QUCG LARC 22/23-499.Scopu